Drug Profile
Rosuvastatin/choline fenofibrate - Abbott Laboratories/AbbVie/AstraZeneca
Alternative Names: ABT-143; ABT-335/rosuvastatin; Certriad; choline-fenofibrate/rosuvastatin; Rosuvastatin/ABT-335; Rosuvastatin/fenofibric acid delayed releaseLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Abbott Laboratories; AstraZeneca
- Class Antihyperlipidaemics; Chlorobenzenes; Ethanolamines; Fibric acid derivatives; Fluorobenzenes; Propionates; Pyrimidines; Small molecules; Sulfonamides
- Mechanism of Action HMG-CoA reductase inhibitors; Peroxisome proliferator-activated receptor alpha agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Hyperlipidaemia
Most Recent Events
- 22 Dec 2010 Discontinued - Preregistration for Hyperlipidaemia in USA (PO)
- 30 Mar 2010 AstraZeneca & Abbott receive complete response letter from the FDA for rosuvastatin/choline fenofibrate in Hyperlipidaemia
- 19 Jun 2009 Post-hoc efficacy data from two phase III trials in Dyslipidaemia presented at the 69th Annual Scientific Sessions of the American Diabetes Association (ADA-2009)